Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 16,130 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Ocular Rosacea, Antimicrobial Resistance
Interventions: Doxycycline 40 MG ( 20mg twice daily), Doxycycline 200 MG ( 100 mg twice daily), Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Interventions: JAB-2485 (Aurora A inhibitor); Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Detroit, Michigan • St Louis, Missouri • Dallas, Texas + 1 more

Conditions: Breast Cancer
Interventions: Abemaciclib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus
Interventions: CUG252, Placebo; Drug
Lead sponsor: Cugene Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Early-Stage Breast Carcinoma
Interventions: Cyrcadia CBR™ device placement for abnormality screening; Device
Lead sponsor: Cyrcadia Health; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Mountain View, California • Columbus, Ohio

Conditions: Breast Cancer, Metastases
Interventions: Ixabepilone + Capecitabine, Capecitabine; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 32
States / cities: Little Rock, Arkansas • San Francisco, California • Vallejo, California + 29 more

Conditions: Alopecia Areata(AA)
Interventions: HCW9302, an IL-2 fusion protein; Drug
Lead sponsor: HCW Biologics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio

Conditions: Systemic Lupus Erythematosus
Interventions: TENS for vagus stimulation, TENS for sham stimulation; Device
Lead sponsor: Aikaterini Thanou; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Advanced Unresectable Melanoma, Metastatic Melanoma
Interventions: Mirdametinib; Drug
Lead sponsor: Kevin Kim, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions: GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)]); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Scabies
Interventions: Permethrin Cream, 5%, Elimite™ Cream (permethrin) 5%; Drug
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 2 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 10
States / cities: Little Rock, Arkansas • Anaheim, California • Long Beach, California + 7 more

Conditions: Vaginitis, Dyspareunia, Breast Neoplasms
Interventions: Testosterone propionate; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Pawtucket, Rhode Island • Burlington, Vermont

Conditions: Atopic Dermatitis
Interventions: AD printed educational materials, AD educational videos; Other
Lead sponsor: Boston University; Other
Eligibility: Up to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: Secukinumab, Placebo followed by Secukinumab; Drug
Lead sponsor: James G. Krueger, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Hormone Dependent Neoplasms, Adherence to Hormone Therapy
Interventions: "OncoTool" Intervention (MBSR + HT education), "Oncotool" Control (health +HT education); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma (Skin)
Interventions: bevacizumab, carboplatin, everolimus, paclitaxel; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 310
States / cities: Scottsdale, Arizona • Martinez, California • Mountain View, California + 214 more

Conditions: Acne Vulgaris
Interventions: Tazarotene Foam, Vehicle Foam; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Alopecia, Androgenetic
Interventions: Clascoterone 5% solution, Vehicle solution; Drug
Lead sponsor: Cassiopea SpA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more

Conditions: Breast Cancer, Postoperative Pain, Opioid Use, Local Anesthesia
Interventions: Pectoral Nerve Block, Surgery without Nerve Block; Procedure
Lead sponsor: Main Line Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Baseline Questionnaire, Semi structured Interview, Post Survey; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Psoriasis
Interventions: MM-093; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Dallas, Texas • Salt Lake City, Utah

Conditions: Papulopustular Rosacea
Interventions: Secukinumab; Drug
Lead sponsor: Anne Chang; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Redwood City, California

Search by objective public record fields.

Ocular Rosacea Biome Study

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

Circadian Thermal Sensing to Detect Breast Disease

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

Transcutaneous Vagus Nerve Stimulation for the Treatment of Lupus

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

Clinic-Based Atopic Dermatitis Therapeutic Patient Education

Safety and Efficacy of Secukinumab in Mild Psoriasis

A Web-Based Tool to Improve Breast Cancer Survivorship

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

PECS Block in Partial Mastectomy for Postoperative Pain Control

Dissemination of BREASTChoice AIM1-B

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea